United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis
Background Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. Methods A...
Gespeichert in:
Veröffentlicht in: | United European gastroenterology journal 2021-04, Vol.9 (3), p.287-306 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 306 |
---|---|
container_issue | 3 |
container_start_page | 287 |
container_title | United European gastroenterology journal |
container_volume | 9 |
creator | Schol, Jolien Wauters, Lucas Dickman, Ram Drug, Vasile Mulak, Agata Serra, Jordi Enck, Paul Tack, Jan |
description | Background
Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis.
Methods
A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements.
Results
The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT4 receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause.
Conclusions and Inferences
A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis.
Key Summary
Current knowledge
The epidemiology of gastroparesis is not well known.
Diagnosis and treatment of gastroparesis is challenging due to uncertainties in definition and optimal therapeutic approach.
What is new here
A Delphi panel consisting of 40 experts from 19 European countries established the level of consensus on 89 statements regarding gastroparesis.
The statements reaching c |
doi_str_mv | 10.1002/ueg2.12060 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8259275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2522195493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5140-9fb2e963faf3da0313960f0583bb723cef57c38e5e477bf76e7fb783946743573</originalsourceid><addsrcrecordid>eNp9kU9LHDEYh0OpVFEv_QAl0MsqrM3fyeRSEFm3BbUHu-eQmX2zjcwm22SmZe9-cLMdu1gPzSUhed4fv_Ag9J6SC0oI-zTAil1QRiryBh0xIsm0ElS83Z9JdYhOc34gZdW1YEy8Q4eca65rzY7Q4yL4HpZ4NqS4ARvw3OY-RQg9pNjF1RZPFrP5GbbhBXMfWw_9FruY8B2U29XroR1-G3vf-YJNZvd3t2e4jSFDyEPGMeBxYmMTZJ9P0IGzXYbT5_0YLa5n36--TG--zb9eXd5MW0kFmWrXMNAVd9bxpSWccl0RR2TNm0Yx3oKTquU1SBBKNU5VoFyjaq5FpQSXih-jz2PuZmjWsGxL4WQ7s0l-bdPWROvNvy_B_zCr-MvUTGqmZAmYPAek-HOA3Ju1zy10nQ0Qh2yYZIxqKTQv6MdX6EMcUijfM5xoUmtdMVqo85FqU8w5gduXocTs_JqdX_PHb4E_vKy_R__aLAAdgd--g-1_okxxysbQJ9PMsVQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090899621</pqid></control><display><type>article</type><title>United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis</title><source>MEDLINE</source><source>Wiley-Blackwell Open Access Titles</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Schol, Jolien ; Wauters, Lucas ; Dickman, Ram ; Drug, Vasile ; Mulak, Agata ; Serra, Jordi ; Enck, Paul ; Tack, Jan</creator><creatorcontrib>Schol, Jolien ; Wauters, Lucas ; Dickman, Ram ; Drug, Vasile ; Mulak, Agata ; Serra, Jordi ; Enck, Paul ; Tack, Jan ; ESNM Gastroparesis Consensus Group ; the ESNM Gastroparesis Consensus Group</creatorcontrib><description>Background
Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis.
Methods
A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements.
Results
The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT4 receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause.
Conclusions and Inferences
A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis.
Key Summary
Current knowledge
The epidemiology of gastroparesis is not well known.
Diagnosis and treatment of gastroparesis is challenging due to uncertainties in definition and optimal therapeutic approach.
What is new here
A Delphi panel consisting of 40 experts from 19 European countries established the level of consensus on 89 statements regarding gastroparesis.
The statements reaching consensus serve to guide clinicians in recognizing, diagnosing and treating gastroparesis in clinical practice.
The statements without consensus identify areas in need of future research.</description><identifier>ISSN: 2050-6406</identifier><identifier>ISSN: 2050-6414</identifier><identifier>EISSN: 2050-6414</identifier><identifier>DOI: 10.1002/ueg2.12060</identifier><identifier>PMID: 33939892</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Abdomen ; Asymptomatic ; Consensus ; Delphi Technique ; Diabetes ; Diet Therapy ; Dopamine D2 Receptor Antagonists - therapeutic use ; Dyspepsia - etiology ; endoscopy ; Endoscopy, Gastrointestinal ; Europe ; gastric emptying ; Gastric Emptying - physiology ; Gastroenterology ; gastroparesis ; Gastroparesis - complications ; Gastroparesis - diagnosis ; Gastroparesis - physiopathology ; Gastroparesis - therapy ; guideline ; Humans ; Likert scale ; Literature reviews ; Motility ; Nausea ; Nausea - etiology ; Neurogastroenterology ; Neurology ; Nutritional Support ; Original ; Postprandial Period ; prokinetic ; Risk Factors ; Serotonin Receptor Agonists ; Societies, Medical ; Symptom Assessment ; Vomiting ; Vomiting - etiology ; Working groups</subject><ispartof>United European gastroenterology journal, 2021-04, Vol.9 (3), p.287-306</ispartof><rights>2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5140-9fb2e963faf3da0313960f0583bb723cef57c38e5e477bf76e7fb783946743573</citedby><cites>FETCH-LOGICAL-c5140-9fb2e963faf3da0313960f0583bb723cef57c38e5e477bf76e7fb783946743573</cites><orcidid>0000-0002-6477-2849 ; 0000-0002-3206-6704 ; 0000-0003-4678-8393</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259275/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259275/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33939892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schol, Jolien</creatorcontrib><creatorcontrib>Wauters, Lucas</creatorcontrib><creatorcontrib>Dickman, Ram</creatorcontrib><creatorcontrib>Drug, Vasile</creatorcontrib><creatorcontrib>Mulak, Agata</creatorcontrib><creatorcontrib>Serra, Jordi</creatorcontrib><creatorcontrib>Enck, Paul</creatorcontrib><creatorcontrib>Tack, Jan</creatorcontrib><creatorcontrib>ESNM Gastroparesis Consensus Group</creatorcontrib><creatorcontrib>the ESNM Gastroparesis Consensus Group</creatorcontrib><title>United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis</title><title>United European gastroenterology journal</title><addtitle>United European Gastroenterol J</addtitle><description>Background
Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis.
Methods
A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements.
Results
The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT4 receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause.
Conclusions and Inferences
A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis.
Key Summary
Current knowledge
The epidemiology of gastroparesis is not well known.
Diagnosis and treatment of gastroparesis is challenging due to uncertainties in definition and optimal therapeutic approach.
What is new here
A Delphi panel consisting of 40 experts from 19 European countries established the level of consensus on 89 statements regarding gastroparesis.
The statements reaching consensus serve to guide clinicians in recognizing, diagnosing and treating gastroparesis in clinical practice.
The statements without consensus identify areas in need of future research.</description><subject>Abdomen</subject><subject>Asymptomatic</subject><subject>Consensus</subject><subject>Delphi Technique</subject><subject>Diabetes</subject><subject>Diet Therapy</subject><subject>Dopamine D2 Receptor Antagonists - therapeutic use</subject><subject>Dyspepsia - etiology</subject><subject>endoscopy</subject><subject>Endoscopy, Gastrointestinal</subject><subject>Europe</subject><subject>gastric emptying</subject><subject>Gastric Emptying - physiology</subject><subject>Gastroenterology</subject><subject>gastroparesis</subject><subject>Gastroparesis - complications</subject><subject>Gastroparesis - diagnosis</subject><subject>Gastroparesis - physiopathology</subject><subject>Gastroparesis - therapy</subject><subject>guideline</subject><subject>Humans</subject><subject>Likert scale</subject><subject>Literature reviews</subject><subject>Motility</subject><subject>Nausea</subject><subject>Nausea - etiology</subject><subject>Neurogastroenterology</subject><subject>Neurology</subject><subject>Nutritional Support</subject><subject>Original</subject><subject>Postprandial Period</subject><subject>prokinetic</subject><subject>Risk Factors</subject><subject>Serotonin Receptor Agonists</subject><subject>Societies, Medical</subject><subject>Symptom Assessment</subject><subject>Vomiting</subject><subject>Vomiting - etiology</subject><subject>Working groups</subject><issn>2050-6406</issn><issn>2050-6414</issn><issn>2050-6414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kU9LHDEYh0OpVFEv_QAl0MsqrM3fyeRSEFm3BbUHu-eQmX2zjcwm22SmZe9-cLMdu1gPzSUhed4fv_Ag9J6SC0oI-zTAil1QRiryBh0xIsm0ElS83Z9JdYhOc34gZdW1YEy8Q4eca65rzY7Q4yL4HpZ4NqS4ARvw3OY-RQg9pNjF1RZPFrP5GbbhBXMfWw_9FruY8B2U29XroR1-G3vf-YJNZvd3t2e4jSFDyEPGMeBxYmMTZJ9P0IGzXYbT5_0YLa5n36--TG--zb9eXd5MW0kFmWrXMNAVd9bxpSWccl0RR2TNm0Yx3oKTquU1SBBKNU5VoFyjaq5FpQSXih-jz2PuZmjWsGxL4WQ7s0l-bdPWROvNvy_B_zCr-MvUTGqmZAmYPAek-HOA3Ju1zy10nQ0Qh2yYZIxqKTQv6MdX6EMcUijfM5xoUmtdMVqo85FqU8w5gduXocTs_JqdX_PHb4E_vKy_R__aLAAdgd--g-1_okxxysbQJ9PMsVQ</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Schol, Jolien</creator><creator>Wauters, Lucas</creator><creator>Dickman, Ram</creator><creator>Drug, Vasile</creator><creator>Mulak, Agata</creator><creator>Serra, Jordi</creator><creator>Enck, Paul</creator><creator>Tack, Jan</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6477-2849</orcidid><orcidid>https://orcid.org/0000-0002-3206-6704</orcidid><orcidid>https://orcid.org/0000-0003-4678-8393</orcidid></search><sort><creationdate>202104</creationdate><title>United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis</title><author>Schol, Jolien ; Wauters, Lucas ; Dickman, Ram ; Drug, Vasile ; Mulak, Agata ; Serra, Jordi ; Enck, Paul ; Tack, Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5140-9fb2e963faf3da0313960f0583bb723cef57c38e5e477bf76e7fb783946743573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Abdomen</topic><topic>Asymptomatic</topic><topic>Consensus</topic><topic>Delphi Technique</topic><topic>Diabetes</topic><topic>Diet Therapy</topic><topic>Dopamine D2 Receptor Antagonists - therapeutic use</topic><topic>Dyspepsia - etiology</topic><topic>endoscopy</topic><topic>Endoscopy, Gastrointestinal</topic><topic>Europe</topic><topic>gastric emptying</topic><topic>Gastric Emptying - physiology</topic><topic>Gastroenterology</topic><topic>gastroparesis</topic><topic>Gastroparesis - complications</topic><topic>Gastroparesis - diagnosis</topic><topic>Gastroparesis - physiopathology</topic><topic>Gastroparesis - therapy</topic><topic>guideline</topic><topic>Humans</topic><topic>Likert scale</topic><topic>Literature reviews</topic><topic>Motility</topic><topic>Nausea</topic><topic>Nausea - etiology</topic><topic>Neurogastroenterology</topic><topic>Neurology</topic><topic>Nutritional Support</topic><topic>Original</topic><topic>Postprandial Period</topic><topic>prokinetic</topic><topic>Risk Factors</topic><topic>Serotonin Receptor Agonists</topic><topic>Societies, Medical</topic><topic>Symptom Assessment</topic><topic>Vomiting</topic><topic>Vomiting - etiology</topic><topic>Working groups</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schol, Jolien</creatorcontrib><creatorcontrib>Wauters, Lucas</creatorcontrib><creatorcontrib>Dickman, Ram</creatorcontrib><creatorcontrib>Drug, Vasile</creatorcontrib><creatorcontrib>Mulak, Agata</creatorcontrib><creatorcontrib>Serra, Jordi</creatorcontrib><creatorcontrib>Enck, Paul</creatorcontrib><creatorcontrib>Tack, Jan</creatorcontrib><creatorcontrib>ESNM Gastroparesis Consensus Group</creatorcontrib><creatorcontrib>the ESNM Gastroparesis Consensus Group</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>United European gastroenterology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schol, Jolien</au><au>Wauters, Lucas</au><au>Dickman, Ram</au><au>Drug, Vasile</au><au>Mulak, Agata</au><au>Serra, Jordi</au><au>Enck, Paul</au><au>Tack, Jan</au><aucorp>ESNM Gastroparesis Consensus Group</aucorp><aucorp>the ESNM Gastroparesis Consensus Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis</atitle><jtitle>United European gastroenterology journal</jtitle><addtitle>United European Gastroenterol J</addtitle><date>2021-04</date><risdate>2021</risdate><volume>9</volume><issue>3</issue><spage>287</spage><epage>306</epage><pages>287-306</pages><issn>2050-6406</issn><issn>2050-6414</issn><eissn>2050-6414</eissn><abstract>Background
Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis.
Methods
A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements.
Results
The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine‐2 antagonists and 5‐HT4 receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long‐term prognosis of gastroparesis depends on the cause.
Conclusions and Inferences
A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis.
Key Summary
Current knowledge
The epidemiology of gastroparesis is not well known.
Diagnosis and treatment of gastroparesis is challenging due to uncertainties in definition and optimal therapeutic approach.
What is new here
A Delphi panel consisting of 40 experts from 19 European countries established the level of consensus on 89 statements regarding gastroparesis.
The statements reaching consensus serve to guide clinicians in recognizing, diagnosing and treating gastroparesis in clinical practice.
The statements without consensus identify areas in need of future research.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>33939892</pmid><doi>10.1002/ueg2.12060</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0002-6477-2849</orcidid><orcidid>https://orcid.org/0000-0002-3206-6704</orcidid><orcidid>https://orcid.org/0000-0003-4678-8393</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2050-6406 |
ispartof | United European gastroenterology journal, 2021-04, Vol.9 (3), p.287-306 |
issn | 2050-6406 2050-6414 2050-6414 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8259275 |
source | MEDLINE; Wiley-Blackwell Open Access Titles; Wiley Online Library All Journals; PubMed Central |
subjects | Abdomen Asymptomatic Consensus Delphi Technique Diabetes Diet Therapy Dopamine D2 Receptor Antagonists - therapeutic use Dyspepsia - etiology endoscopy Endoscopy, Gastrointestinal Europe gastric emptying Gastric Emptying - physiology Gastroenterology gastroparesis Gastroparesis - complications Gastroparesis - diagnosis Gastroparesis - physiopathology Gastroparesis - therapy guideline Humans Likert scale Literature reviews Motility Nausea Nausea - etiology Neurogastroenterology Neurology Nutritional Support Original Postprandial Period prokinetic Risk Factors Serotonin Receptor Agonists Societies, Medical Symptom Assessment Vomiting Vomiting - etiology Working groups |
title | United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A35%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=United%20European%20Gastroenterology%20(UEG)%20and%20European%20Society%20for%20Neurogastroenterology%20and%20Motility%20(ESNM)%20consensus%20on%20gastroparesis&rft.jtitle=United%20European%20gastroenterology%20journal&rft.au=Schol,%20Jolien&rft.aucorp=ESNM%20Gastroparesis%20Consensus%20Group&rft.date=2021-04&rft.volume=9&rft.issue=3&rft.spage=287&rft.epage=306&rft.pages=287-306&rft.issn=2050-6406&rft.eissn=2050-6414&rft_id=info:doi/10.1002/ueg2.12060&rft_dat=%3Cproquest_pubme%3E2522195493%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3090899621&rft_id=info:pmid/33939892&rfr_iscdi=true |